- Home
- MAGH vs CVM Comparison
MAGH vs CVM Comparison
Compare MAGH & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAGH
- CVM
- Stock Information
- Founded
- MAGH 2012
- CVM 1983
- Country
- MAGH Singapore
- CVM United States
- Employees
- MAGH N/A
- CVM N/A
- Industry
- MAGH Engineering & Construction
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAGH Industrials
- CVM Health Care
- Exchange
- MAGH Nasdaq
- CVM Nasdaq
- Market Cap
- MAGH 51.8M
- CVM 60.9M
- IPO Year
- MAGH 2025
- CVM 1987
- Fundamental
- Price
- MAGH $1.67
- CVM $8.61
- Analyst Decision
- MAGH
- CVM
- Analyst Count
- MAGH 0
- CVM 0
- Target Price
- MAGH N/A
- CVM N/A
- AVG Volume (30 Days)
- MAGH 210.5K
- CVM 72.3K
- Earning Date
- MAGH 11-08-2025
- CVM 08-14-2025
- Dividend Yield
- MAGH N/A
- CVM N/A
- EPS Growth
- MAGH N/A
- CVM N/A
- EPS
- MAGH 0.00
- CVM N/A
- Revenue
- MAGH $11,752,129.00
- CVM N/A
- Revenue This Year
- MAGH N/A
- CVM N/A
- Revenue Next Year
- MAGH N/A
- CVM N/A
- P/E Ratio
- MAGH $1,777.24
- CVM N/A
- Revenue Growth
- MAGH N/A
- CVM N/A
- 52 Week Low
- MAGH $0.99
- CVM $1.98
- 52 Week High
- MAGH $5.15
- CVM $32.70
- Technical
- Relative Strength Index (RSI)
- MAGH N/A
- CVM 42.29
- Support Level
- MAGH N/A
- CVM $8.50
- Resistance Level
- MAGH N/A
- CVM $9.35
- Average True Range (ATR)
- MAGH 0.00
- CVM 0.63
- MACD
- MAGH 0.00
- CVM -0.13
- Stochastic Oscillator
- MAGH 0.00
- CVM 20.54
About MAGH Magnitude International Ltd Ordinary Shares
Magnitude International Ltd is providing electrical installation services to customers in both the private and public sectors in Singapore. It includes the planning, design, material selection, installation, testing, commissioning and certification of the electrical equipment/systems to be installed. The Group's revenue is derived from Singapore.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.